Ndatalyze's Epitome analyzes hockey player performance

Mr. Jim Durward reports NDATALYZE CORP. ANNOUNCES INITIATION OF "EPITOME", A PREDICTIVE SPORTS PERFORMANCE PROJECT LEVERAGING AI TO ADDRESS A MULTI-BILLION DOLLAR SPORTS ANALYTICS MARKET Ndatalyze Corp. has initiated Epitome, a next-generation sports performance analytic project designed to apply advanced machine learning to professional hockey performance. The project builds upon Ndatalyze's clinically validated emotional state/performance assessment platform and represents a strategic move into the fast-growing global sports analytic market, projected to surpass $22-billion (U.S.) by 2030. Value proposition Epitome leverages proprietary biometric modelling technology to address one of the most financially consequential challenges in professional sports: accurately predicting athletic performance. With NHL teams investing millions in draft picks, trades and long-term contracts, the ability to more reliably forecast player success could materially reduce risk and increase returns for franchises. By extension, this creates significant commercial potential for Epitome, positioning Ndatalyze at the intersection of artificial intelligence, genomics and sports analytics. Project overview: Signature modelling: Epitome creates a unique signature for each player by combining biometric data, performance statistics, genetic predispositions and algorithmic scores. Ground truth benchmarking: The system compares individual signatures against those of proven high performance players (forwards and defence) to establish predictive benchmarks. Applications: Assessing future performance prospects before acquisitions or trades; Optimizing roster configurations to strengthen team performance; Developing personalized coaching and training protocols to maximize player outcomes. Industry demand and economic rationale The risks associated with player drafting and development are well documented. Only 19 per cent of NHL draftees play more than 200 games, underscoring the billions of dollars lost to inefficiencies in talent selection. Jim Durward, Ndatalyze president, noted: "The draft is an inherently risky, multimillion-dollar gamble. By adapting our clinically studied Sigmund algorithms for sports applications, we are building a valuation tool that may significantly derisk these decisions. Our goal is to create a disruptive edge in professional hockey, with potential scalability across other major sports." Progress and strategic positioning: Ndatalyze has already secured commitments from three advisers (two former NHL coaches and one university-level coach) to help define the digital high performance player. Additional pathways to former NHL players are being developed. The project is fully financed through existing cash on hand, ensuring no dilution to shareholders at this stage. Importantly, the previously announced reverse takeover continues to advance, with Epitome included in the proposed spinout. This means pre-RTO Ndatalyze shareholders will directly benefit from the project whether or not the RTO closes. Epitome underscores Ndatalyze's commitment to commercializing its proprietary artificial-intelligence-driven biometric technology across multiple high-value verticals. By targeting a multibillion-dollar global market with a unique, clinically grounded solution, Ndatalyze believes Epitome has the potential to deliver meaningful shareholder value while positioning the corporation as a leader in the convergence of AI and predictive sports performance analytics. We seek Safe Harbor.